Future directions in adjuvant therapy for stage III colon carcinoma

Henry Clement Pitot, Richard M. Goldberg

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The current recommendation for adjuvant chemotherapy for patients with newly diagnosed stage III colon cancer in volves 6 months of fluorouracil (5-FU) plus low- or high-dose leucovorin. In clinical trials performed throughout the world, several drugs have demonstrated either improved toxicity profiles or antitumor activity for patients with advanced colorectal carcinoma. Uracil and tegafur (UFT) and capecitabine (Xeloda) are two examples of new oral chemotherapy compounds with acceptable side-effect profiles in early adjuvant or advanced disease trials. Irinotecan (CPT-11, Camptosar) and oxaliplatin, when administered intravenously in combination with a 5-FU regimen, have both demonstrated significant antitumor effects for patients with advanced-stage disease. Other immunotherapies, including monoclonal antibodies and cancer vaccines, are being evaluated to help stimulate immune responses in patients with resected colon cancer. These agents are just a few examples of the new compounds being tested in the next generation of clinical trials for resected stage III colon cancer. Future and ongoing investigations will look to integrate these new therapies as we attempt to move beyond the era of 5-FU and leucovorin.

Original languageEnglish (US)
Pages (from-to)31-36
Number of pages6
JournalOncology
Volume15
Issue number3 SUPPL. 5
StatePublished - 2001

Fingerprint

irinotecan
Colon
Fluorouracil
Colonic Neoplasms
Carcinoma
oxaliplatin
Leucovorin
Clinical Trials
Tegafur
Cancer Vaccines
Uracil
Therapeutics
Adjuvant Chemotherapy
Immunotherapy
Colorectal Neoplasms
Monoclonal Antibodies
Drug Therapy
Direction compound
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Future directions in adjuvant therapy for stage III colon carcinoma. / Pitot, Henry Clement; Goldberg, Richard M.

In: Oncology, Vol. 15, No. 3 SUPPL. 5, 2001, p. 31-36.

Research output: Contribution to journalArticle

Pitot, HC & Goldberg, RM 2001, 'Future directions in adjuvant therapy for stage III colon carcinoma', Oncology, vol. 15, no. 3 SUPPL. 5, pp. 31-36.
Pitot, Henry Clement ; Goldberg, Richard M. / Future directions in adjuvant therapy for stage III colon carcinoma. In: Oncology. 2001 ; Vol. 15, No. 3 SUPPL. 5. pp. 31-36.
@article{4659a8042b2640178c28d53670209f58,
title = "Future directions in adjuvant therapy for stage III colon carcinoma",
abstract = "The current recommendation for adjuvant chemotherapy for patients with newly diagnosed stage III colon cancer in volves 6 months of fluorouracil (5-FU) plus low- or high-dose leucovorin. In clinical trials performed throughout the world, several drugs have demonstrated either improved toxicity profiles or antitumor activity for patients with advanced colorectal carcinoma. Uracil and tegafur (UFT) and capecitabine (Xeloda) are two examples of new oral chemotherapy compounds with acceptable side-effect profiles in early adjuvant or advanced disease trials. Irinotecan (CPT-11, Camptosar) and oxaliplatin, when administered intravenously in combination with a 5-FU regimen, have both demonstrated significant antitumor effects for patients with advanced-stage disease. Other immunotherapies, including monoclonal antibodies and cancer vaccines, are being evaluated to help stimulate immune responses in patients with resected colon cancer. These agents are just a few examples of the new compounds being tested in the next generation of clinical trials for resected stage III colon cancer. Future and ongoing investigations will look to integrate these new therapies as we attempt to move beyond the era of 5-FU and leucovorin.",
author = "Pitot, {Henry Clement} and Goldberg, {Richard M.}",
year = "2001",
language = "English (US)",
volume = "15",
pages = "31--36",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "3 SUPPL. 5",

}

TY - JOUR

T1 - Future directions in adjuvant therapy for stage III colon carcinoma

AU - Pitot, Henry Clement

AU - Goldberg, Richard M.

PY - 2001

Y1 - 2001

N2 - The current recommendation for adjuvant chemotherapy for patients with newly diagnosed stage III colon cancer in volves 6 months of fluorouracil (5-FU) plus low- or high-dose leucovorin. In clinical trials performed throughout the world, several drugs have demonstrated either improved toxicity profiles or antitumor activity for patients with advanced colorectal carcinoma. Uracil and tegafur (UFT) and capecitabine (Xeloda) are two examples of new oral chemotherapy compounds with acceptable side-effect profiles in early adjuvant or advanced disease trials. Irinotecan (CPT-11, Camptosar) and oxaliplatin, when administered intravenously in combination with a 5-FU regimen, have both demonstrated significant antitumor effects for patients with advanced-stage disease. Other immunotherapies, including monoclonal antibodies and cancer vaccines, are being evaluated to help stimulate immune responses in patients with resected colon cancer. These agents are just a few examples of the new compounds being tested in the next generation of clinical trials for resected stage III colon cancer. Future and ongoing investigations will look to integrate these new therapies as we attempt to move beyond the era of 5-FU and leucovorin.

AB - The current recommendation for adjuvant chemotherapy for patients with newly diagnosed stage III colon cancer in volves 6 months of fluorouracil (5-FU) plus low- or high-dose leucovorin. In clinical trials performed throughout the world, several drugs have demonstrated either improved toxicity profiles or antitumor activity for patients with advanced colorectal carcinoma. Uracil and tegafur (UFT) and capecitabine (Xeloda) are two examples of new oral chemotherapy compounds with acceptable side-effect profiles in early adjuvant or advanced disease trials. Irinotecan (CPT-11, Camptosar) and oxaliplatin, when administered intravenously in combination with a 5-FU regimen, have both demonstrated significant antitumor effects for patients with advanced-stage disease. Other immunotherapies, including monoclonal antibodies and cancer vaccines, are being evaluated to help stimulate immune responses in patients with resected colon cancer. These agents are just a few examples of the new compounds being tested in the next generation of clinical trials for resected stage III colon cancer. Future and ongoing investigations will look to integrate these new therapies as we attempt to move beyond the era of 5-FU and leucovorin.

UR - http://www.scopus.com/inward/record.url?scp=0035292311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035292311&partnerID=8YFLogxK

M3 - Article

C2 - 11301838

AN - SCOPUS:0035292311

VL - 15

SP - 31

EP - 36

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3 SUPPL. 5

ER -